Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.98 |
| ▸ | MAPT | P10636 | 6/20 | 0.98 |
| ▸ | HPGD | P15428 | 6/20 | 0.98 |
| ▸ | GLA | P06280 | 2/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.98 |
| ▸ | RAD52 | P43351 | 2/20 | 0.98 |
| ▸ | DRD2 | P14416 | 7/20 | 0.77 |
| ▸ | PKM | P14618 | 4/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | TP53 | P04637 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apocideine SCHEMBL154292 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP3A4CYP2C19CYP2D6 | |
| Apocideine SCHEMBL29726722 | 1.00 | HSD17B10 (1.00) | HSD17B10CYP1A2CYP3A4CYP2C19CYP2D6 | |
| Apocideine SCHEMBL7914642 | 0.99 | ALDH1A1 (1.00) | HSD17B10CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL25468978 | 0.88 | HSD17B10 (0.78) | HSD17B10CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL21040947 | 0.88 | HSD17B10 (0.78) | HSD17B10CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL5313458 | 0.87 | DRD2 (1.00) | HSD17B10CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL14494966 | 0.87 | DRD2 (1.00) | HSD17B10CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL29726679 | 0.87 | DRD2 (1.00) | HSD17B10CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL20996579 | 0.86 | HSD17B10 (0.75) | HSD17B10CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL20996588 | 0.86 | HSD17B10 (0.75) | HSD17B10CYP1A2CYP3A4CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110585165-B | Abuse resistant capsules | R·P·谢勒技术有限公司 | 2022-08-12 | — | — | CN | claimed |
| WO-2023085420-A1 | FERROPTOSIS INHIBITOR AND USE THEREFOR | 学校法人自治医科大学 | 2023-05-19 | — | — | WO | disclosed |
| US-20230141988-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | ACLIPSE ONE INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230141988-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | ACLIPSE ONE INC. | 2023-05-11 | — | — | US | disclosed |
| CN-110585165-B | Abuse resistant capsules | R·P·谢勒技术有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-8063060-B2 | R(−)-11-hydroxyaporphine derivatives and uses thereof | THE MCLEAN HOSPITAL CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100081651-A1 | R(-)-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-04-01 | — | — | US | disclosed |
| US-7648995-B2 | R(—)-11-hydroxyaporphine derivatives and uses thereof | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-01-19 | — | — | US | disclosed |
| US-20060040900-A1 | R(-)-11-hydroxyaporphine derivatives and uses thereof | MCLEAN HOSPITAL CORPORATION, THE | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040900-A1 | R(-)-11-hydroxyaporphine derivatives and uses thereof | SNCA, HTR5A, PARK7 | HSD17B10 191/4885CYP1A2 224/4885CYP3A4 537/4885 |
| US-20100081651-A1 | R(-)-11-HYDROXYAPORPHINE DERIVATIVES AND USES THEREOF | SNCA, HTR5A, HTR3A | HSD17B10 197/4885CYP1A2 241/4885CYP3A4 572/4885 |
| US-20230141988-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | PARK7, SNCA, ATXN10 | HSD17B10 606/4885CYP1A2 411/4885CYP3A4 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.